EMEA-001741-PIP01-14-M04

Table of contents

Key facts

Invented name
Rinvoq
Active substance
upadacitinib
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0167/2021
PIP number
EMEA-001741-PIP01-14-M04
Pharmaceutical form(s)
  • Age-appropriate oral solid dosage form
  • Age-appropriate oral liquid dosage form
  • Prolonged-release tablet
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)
Route(s) of administration
Oral use
Contact for public enquiries
AbbVie Ltd

Tel.: +44 1628408248
E-mail: paediatricteam@abbvie.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating